Spanish Menopause Society position statement: Use of tibolone in postmenopausal women

Menopause

Volumn 20, Issue 7, 2013, Pages 754-760

  Mendoza, Nicolás ^a   Abad, Pedro ^b   Baró, Francesc ^c   Cancelo, Ma Jesús ^d   Llaneza, Plácido ^e   Manubens, Montserrat ^f   Quereda, Francisco ^g   Sánchez Borrego, Rafael ^h  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL TORRECÁRDENAS   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF ALCALÁ   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f INSTITUT UNIVERSITARI DEXEUS   (Spain)

^g MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^h Clinica Diatros   (Spain)

Author keywords

Hormone therapy; Postmenopausal; Tibolone

Indexed keywords

ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; HORMONE; PLACEBO; RALOXIFENE; TESTOSTERONE; TIBOLONE;

ARTICLE; BREAST CANCER; CARDIOVASCULAR EFFECT; CEREBROVASCULAR ACCIDENT; COLON CANCER; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FRACTURE; HEMOSTASIS; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; MASTALGIA; MOOD DISORDER; NONHUMAN; OSTEOPOROSIS; OVARY CARCINOMA; POSTMENOPAUSE; QUALITY OF LIFE; SEXUAL DYSFUNCTION; SEXUALITY; SIDE EFFECT; SPOTTING; VAGINA BLEEDING; VASOMOTOR DISORDER;

AGED; BONE DENSITY; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SOCIETIES, MEDICAL; SPAIN;

EID: 84879983071     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31827b18c5     Document Type: Article

References (60)

1. Kloosterboer HJ. Tissue-selectivity: the mechanism of action of tibolone. Maturitas 2004;48:S30-S40.
2. Choudhary MI, Shah SA, Atta ur R, Khan SN, Khan MT. α-Glucosidase and tyrosinase inhibitors from fungal hydroxylation of tibolone and hydroxytibolones. Steroids 2010;75:956-966.
3. Formoso G, Perrone E, Maltoni S, et al. Short and long term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev 2012; 2:CD008536.
4. Burbos N, Morris E. Menopausal symptoms. Clin Evid 2010;02:804.
5. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005;51:21-28.
6. Huang KE, Barber R, on behalf of the Asia Pacific Tibolona Consensus Group. Updated clinical recommendations for the use of tibolone in Asian women. Climacteric 2010;13:317-327.
7. Swanson SG, Drosman S, Helmond FA, Stathopoulos VM. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, doubleblind, placebo-controlled study. Menopause 2006;13:917-925.
8. Mendoza N, Pisón JA, Fernández M, Sánchez MC, Malde J, Miranda JA. Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus. Maturitas 2002;41:289-298.
9. Mendoza N, Suárez AM, Alamo F, Bartual E, Vergara F, Herruzo A. Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17β-estradiol for hormonal replacement therapy in women with surgical menopause. Maturitas 2000;37:37-43.
10. Somunkiran A, Erel CT, Demirci F, et al. The effect of Tibolona versus 17β-estradiol on climacteric symptoms in women with surgical menopause: a randomized, cross-over study. Maturitas 2007;56:61-68.
11. Hammar ML, van de Weijer P, Franke HR, et al Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. Br J Obstet Gynaecol 2007;114:1522-1529.
12. Castelo-Branco C, Vicente JJ, Figueras F, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000;34:161-168.
13. 2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008;5:646-656.
14. Cayan F, Dilek U, Pata O, Dilek S. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. J Sex Med 2008;5:132-138.
15. Ziaei S, Moghasemi M, Faghihzadeh S. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric 2010;13:147-156.
16. Nappi RE, Ferdeghini F, Sampaolo P, et al. Clitoral circulation in postmenopausal women with sexual dysfunction: a pilot randomized study with hormone therapy. Maturitas 2006;55:288-295.
17. Nijland EA, Nathorst-Böös J, Palacios S, et al, LISA Study Investigators Group. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. Climacteric 2009;12:114-121.
18. Clarkson TB. Does tibolone exacerbate atherosclerosis? Eur Heart J 2006;27:635-637.
19. Vassalle C, Cicinelli E, Lello S, Mercuri A, Battaglia D, Maffei S. Effects of menopause and tibolone on different cardiovascular biomarkers in healthy women. Gynecol Endocrinol 2011;27:163-169.
20. Engin-Ustün Y, Ustün Y, Türkçüoǧlu I, et al. Short-term effect of tibolone on C-reactive protein in hypertensive postmenopausal women. Arch Gynecol Obstet 2009;279:305-309.
21. Cicinelli E, Ignarro LJ, Galantino P, Pinto V, Barba B, Schonauer S. Effects of tibolone on plasma levels of nitric oxide in postmenopausal women. Fertil Steril 2002;78:464-468.
22. Castelo-Branco C, García-Fantini M, Haya J. Vascular reactivity and atheromatous plaques in post-menopausal women on tibolone treatment: open prospective study with Doppler ultrasonography in internal carotid artery. Maturitas 2005;50:259-265.
23. Lloyd G, McGing E, Cooper A, et al. A randomised placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. J Hum Hypertens 2000;14:99-104.
24. Cagnacci A, Mallus E, Tuveri F, Cirillo R, Setteneri AM, Melis GB. Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1997;82:251-253.
25. Cummings SR, Ettinger B, Delmas PD, et al, LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697-708.
26. Bots ML, Evans GW, Riley W, et al OPAL Investigators. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart 2006;27:746-755.
27. de Souza MA, de Souza BM, Geber S. Vascular resistance of central retinal and ophthalmic arteries in postmenopausal women after use of tibolone. Menopause 2012;19:328-331.
28. Archer DF, Hendrix S, Ferenczy A, et al, THEBES Study Group. Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women. Fertil Steril 2007;88:866-878.
29. Delmas PD, Davis SR, Hensen J, Adami S, van Os S, Nijland EA. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Osteoporos Int 2008;19:1153-1160.
30. Berning B, Bennink HJ, Fauser BC. Tibolone and its effects on bone: a review. Climacteric 2001;4:120-136.
31. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001;86:4717-4726.
32. Bundred NJ, Kenemans P, Yip CH, et al. Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Res 2012;14:R13.
33. http://local.obgyn.net/Tibolone-revisited-Still-a-Good-Treatment-Option- for-Healthy-Early-Postmenopausal-Women-Somerton-AZ-r1257848-Somerton-AZ.html
34. Archer DF, Hendrix S, Gallager JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:911-918.
35. Botsis D, Kassanos D, Kalogirou D, Antoniou G, Vitoratos N, Karakitsos P. Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low dose estrogen or tibolone treatment: a comparison. Maturitas 1997;26:57-62.
36. Meuwissen JH, Wiegerinck MA, Haverkorn MJ. Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy. Maturitas 1995;21:121-125.
37. Rymer J, Fogelman I, Chapman MG. The incidence of vaginal bleeding with tibolone treatment. Br J Obstet Gynaecol 1994;101:53-56.
38. Shapiro S. The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric 2004;7:3-7
39. Gompel A, Chaouat M, Jacob D, Perrot JY, Kloosterboer HJ, Rostene W. In vitro studies of tibolone in breast cells. Fertil Steril 2002;78:351-359.
40. Erel CT, Elter K, Akman C, et al. Mammographic changes in women receiving tibolone therapy. Fertil Steril 1998;69:870-875.
41. Valdivia I, Ortega D. A one year evaluation of mammary radiographic density changes with different HRT regimens in climacteric women. Clin Drug Invest 2000:20:101-107.
42. Beral V, Million Women Study Collaborators. Breast cancer and hormone replacement therapy in Million Women Study. Lancet 2003;362: 419-427.
43. Nelson HD, Fu R, Griffin JC, Nygren P, Smith B, Humphrey L. Systematic review: Comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med 2009:151:703-715.
44. Kenemans P, Bundred NJ, Foidart JM et al, LIBERATE Study Groups. Safety and efficacy of tibolone in breast cancer patient with vasomotor symptoms: a double blind, randomized, non inferiority trial. Lancet Oncol 2009;10:135-146.
45. Lee KB, Lee JM, Yoon JH, Park CY. The safety of tibolone in epithelial ovarian cancer patients. Maturitas 2006;55:156-161.
46. Winkler UH, Altkemper B, Kwee B, Helmond FA, Coelingh Bennink HJ. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, doubleblind, randomized study. Fertil Steril 2000;74:10-19.
47. Skouby SO, Sidelmann JJ, Nilas L, Jespersen J. A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability. Hum Reprod 2007;22:1186-1191.
48. Kaleli B, Yldirim B, Demir S, Alatas E. Effects of low-dose 17-A-estradiol plus norethisterone acetate and tibolone on fasting plasma homocysteine levels in postmenopausal women. Acta Obstet Gynecol Scand 2003;82:1107-1111.
49. Koh KK, Han SH, Shin MS, Ahn JY, Lee Y, Shin EK. Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study. Eur Heart J 2005;26:1362-1368.
50. Norris LA, Joyce M, O'Keeffe N, Sheppard BL, Bonnar J. Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. Maturitas 2002;43:125-133.
51. Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. Thromb Res 2007;120:371-379.
52. Eilertsen AL, LiestLl S, Mowinckel MC, Hemker HC, Sandset PM. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. Thromb Haemost 2007;97:938-943.
53. Martínez-Pino I, Puig T, Quintana MJ, Solà J, Bonfill X. [Prevalence of use of hormone replacement therapy in women participating in a breast cancer screening program]. Med Clin (Barc) 2010;134:439-442.
54. Mosquera Tenreiro C. [Changes in the use of hormone replacement therapy after an educational intervention aimed at women and prescribers]. Gac Sanit 2009;23:100-103.
55. Palacios S, Tobar AC, Menendez C. Sexuality in the climacteric years. Maturitas 2002;43:S69-S77.
56. Palacios S, Menendez C, Jurado AR, Castaño R, Vargas JC. Changes in sex behaviour after menopause: effects of tibolone. Maturitas 1995;22: 155-161.
57. Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009;63:138-141.
58. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979-986.
59. http://www.aemps.gob.es/informa/informeMensual/2011/noviembre/ informe-medicamentos.htm
60. http://cebgrade.mcmaster.ca/